C4 Therapeutics, Inc.
CCCC- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001662579
No open-market purchases or sales by C4 Therapeutics, Inc. insiders were filed in the last 90 days; 147 institutions reported holding it in 13F filings for Q2 2026, worth $547.6M in total; no superinvestor holds it.
Q3 2021 vs. Q2 2021
How the institutions holding C4 Therapeutics, Inc. changed between Q2 2021 and Q3 2021.
All holders in Q3 2021All holders in Q2 2021
| Measure | Q2 2021 | Of which not filed for Q3 2021 | Q3 2021 | Change |
|---|---|---|---|---|
| Holders | 107 | 1 | 113 | +7 |
| Shares | 31.9M | 810.6K | 34.5M | +3.36M (+10.8%) |
| Value | $1.21B | $30.7M | $1.54B | +$363.9M (+30.9%) |
1 institution that held it in Q2 2021 haven't filed for Q3 2021 yet. Not filing isn't selling, so the changes leave them out.
New holders (19)
Institutions that held C4 Therapeutics, Inc. at the end of Q3 2021 but not at the end of Q2 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Pictet Asset Management SA | 1,098,421 | $49.1M | 0.05% |
| Alyeska Investment Group, L.P. | 125,000 | $5.58M | 0.07% |
| Schonfeld Strategic Advisors LLC | 62,253 | $2.78M | 0.03% |
| Federated Hermes, Inc. | 58,612 | $2.62M | 0.00% |
| Jump Financial, LLC | 39,700 | $1.77M | 0.13% |
| Gilder Gagnon Howe & Co LLC | 39,506 | $1.76M | 0.01% |
| Shay Capital LLC | 37,500 | $1.68M | 0.53% |
| Acuta Capital Partners, LLC | 21,000 | $938.0K | 0.33% |
| Pura Vida Investments, LLC | 20,000 | $894.0K | 0.07% |
| Northwestern Mutual Wealth Management Co | 11,679 | $522.0K | 0.00% |
| EMC Capital Management | 10,619 | $472.0K | 0.26% |
| Blueshift Asset Management, LLC | 6,719 | $300.0K | 0.02% |
| Quantbot Technologies LP | 3,700 | $165.0K | 0.01% |
| Migdal Insurance & Financial Holdings Ltd. | 1,194 | $53.0K | 0.00% |
| Rockefeller Capital Management L.P. | 400 | $17.0K | 0.00% |
| Group One Trading, L.P. | 300 | $13.0K | 0.00% |
| Parallel Advisors, LLC | 106 | $5.00K | 0.00% |
| Signaturefd, LLC | 16 | $1.00K | 0.00% |
| Quadrant Capital Group LLC | 4 | $0 | 0.00% |
Sold out (12)
Institutions that held C4 Therapeutics, Inc. at the end of Q2 2021 and filed for Q3 2021 without it.
| Institution | Shares, Q2 2021 | Value, Q2 2021 |
|---|---|---|
| Cormorant Asset Management, LP | 354,495 | $13.4M |
| Maven Securities LTD | 231,925 | $8.96M |
| Mizuho Securities Co. Ltd. | 169,392 | $6.41M |
| Pinz Capital Management, LP | 163,458 | $6.18M |
| Monashee Investment Management LLC | 135,000 | $5.11M |
| Logos Global Management LP | 112,928 | $4.27M |
| Stenahm Asset Managment Ltd | 80,500 | $3.05M |
| Caas Capital Management LP | 63,383 | $2.40M |
| Woodline Partners LP | 25,926 | $981.0K |
| Jacobs Levy Equity Management, Inc | 23,413 | $886.0K |
| Ikarian Capital, LLC | 17,600 | $666.0K |
| JGP Global Gestao de Recursos Ltda. | 6,853 | $259.0K |
Not filed for Q3 2021 yet (1)
Institutions that held C4 Therapeutics, Inc. at the end of Q2 2021 and haven't filed a 13F for Q3 2021. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q2 2021 | Value, Q2 2021 |
|---|---|---|
| Pictet Asset Management Ltd | 810,634 | $30.7M |